Reactive Oxygen Species Gene Signature Predicts Survival in Sepsis

Technology #ua16-068

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Ting Wang
Assistant Professor, Medicine
Nima Pouladi
Postdoctoral Research Associate I, Medicine
Tong Zhou
Research Assistant Professor, Medicine
Christian Bime
Assistant Professor, Medicine
Marvin Slepian
Professor, Medicine
Louise Hecker
Assistant Professor, Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Reactive oxygen species gene signature predicts survival in sepsis


Invention: The technology is a 21-gene reactive oxygen species (ROS)-associated molecular signature that predicts survival in septic patients.  


Background: Sepsis syndrome’s mortality rate is 26% to 82% depending on whether septic shock occurs. Currently there are no reliable diagnostic biomarkers available to predict survival of patients with sepsis. Furthermore, researchers at the University of Arizona understand there is evidence indicating oxidative stress plays a role in the pathogenesis of sepsis.



  • Diagnostic tool and/or service for patients with sepsis



  • Traditional biomarkers (C-reactive protein, interleukin-6, procalcitonin) are not reliable in predicting survival
  • ROS-associated biomarkers were shown to predict the odds of patient’s outcome


Licensing Manager: 

Rakhi Gibbons

(520) 626-6695